V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10442274 | 10057496 | 0 | 61.2 | null | 2017-11-17 | 2017-12-01 | Cetuximab + Oxaliplatin + MdG Maint | 02 | null | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100643558 |
| 10442683 | 10057498 | 1.58 | 71.4 | null | 2019-07-07 | 2019-08-14 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | null | CAPECITABINE + GEMCITABINE | 101579478 |
| 10442870 | 10057499 | 1.6 | 93.3 | null | 2016-12-06 | 2017-06-10 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 02 | null | CYCLOPHOSPHAMIDE + ETOPOSIDE | 100932057 |
| 10443050 | 10057500 | 1.75 | 106.5 | null | 2015-11-06 | 2018-09-21 | R-CHOP / R-DHAP | 99 | null | DOXORUBICIN | 100517493 |
| 10443097 | 10057501 | 1.49 | 0 | Palliative (P) | 2018-01-25 | 2018-02-01 | BRIGATINIB | null | N | PONATINIB | 100035968 |
| 10443134 | 10057502 | 1.65 | 75 | null | 2017-02-10 | 2017-02-22 | Irinotecan + Modified De Gramont | 02 | null | VISMODEGIB | 101088808 |
| 10443207 | 10057503 | 1.74 | 0 | 03 | 2017-05-22 | 2017-05-22 | Epirubicin (weekly) | 02 | N | ETOPOSIDE | 100925145 |
| 10443238 | 10057504 | 1.65 | 89.4 | Palliative (P) | 2016-08-29 | 2016-09-14 | CAV | 02 | N | CAPECITABINE + CISPLATIN | 100560162 |
| 10443345 | 10057505 | 1.66 | 79.15 | null | 2018-03-18 | 2018-09-25 | Ipilimumab | N | null | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 101810969 |
| 10443494 | 10057506 | null | null | Palliative (P) | 2019-07-04 | 2019-07-06 | null | 02 | N | DACARBAZINE | 101130121 |
| 10443511 | 10057507 | 1.69 | 69.5 | null | 2017-03-06 | 2019-03-26 | Folfirinox | N | null | BCG | 100727658 |
| 10443658 | 10057509 | 1.72 | 76.2 | null | 2016-04-22 | 2016-04-22 | VISMODEGIB | 02 | null | MATRIX LYMPHOMA TRIAL | 100368663 |
| 10443699 | 10057510 | 1.52 | 96.8 | Adjuvant (A) | 2019-03-06 | 2019-03-08 | null | 02 | N | MITOMYCIN INTRAVESICULAR | 100521879 |
| 10443746 | 10057511 | 1.63 | 58.8 | Palliative (P) | 2018-12-24 | 2018-12-24 | VISMODEGIB | 02 | N | CAPECITABINE + RT | 101268591 |
| 10443771 | 10057512 | 1.88 | 72.4 | 03 | null | 2020-01-03 | Cisplatin + Radiotherapy | 02 | N | CAPECITABINE + MITOMYCIN | 101318243 |
| 10443867 | 10057513 | 1.48 | 89.4 | Palliative (P) | 2016-10-20 | 2017-03-16 | Cyclophosphamide High Dose | 02 | N | IRINOTECAN + MDG | 101144091 |
| 10443885 | 10057514 | 1.77 | 82.2 | Palliative (P) | 2016-04-11 | 2017-09-17 | Binimetinib + Encorafenib | N | N | MITOMYCIN INTRAVESICULAR | 101100238 |
| 10444165 | 10057518 | 0 | 57.7 | 03 | null | 2019-06-01 | Letrozole + Palbociclib | 02 | N | CAPECITABINE + GEMCITABINE | 100926689 |
| 10444223 | 10057519 | 1.52 | 76.1 | Curative (C) | 2019-07-19 | 2019-07-19 | Vinblastine | 02 | N | MATRIX LYMPHOMA TRIAL | 100703262 |
| 10444458 | 10057520 | 1.69 | 83.5 | null | 2020-06-21 | 2020-07-08 | CHLORAMBUCIL + RITUXIMAB | N | null | IDELALISIB | 100069269 |
| 10444464 | 10057521 | 1.54 | 115 | Palliative (P) | 2017-02-26 | 2017-11-16 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | null | BRIGATINIB | 101142185 |
| 10444611 | 10057522 | null | null | Disease modification (D) | 2022-05-13 | 2022-05-13 | Fulvestrant + Palbociclib | 02 | N | CYTARABINE HIGH DOSE | 101253243 |
| 10444733 | 10057523 | 1.64 | 59.2 | null | 2019-12-20 | 2019-12-22 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | Y | null | ISATUXIMAB | 100441369 |
| 10444770 | 10057524 | 0 | 76.7 | null | 2017-06-21 | 2021-02-13 | null | 02 | null | CYTARABINE + METHOTREXATE + RITUXIMAB | 101371771 |
| 10444774 | 10057525 | 0 | 0 | Palliative (P) | 2017-07-21 | 2017-08-04 | CVP R | 02 | N | CHOP R | 101065119 |
| 10444945 | 10057526 | 1.58 | 54.6 | null | 2002-05-11 | 2017-04-09 | Cytarabine Low Dose | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101669086 |
| 10444972 | 10057527 | 1.55 | 0 | Curative (C) | 2018-08-14 | 2020-10-16 | ANAGRELIDE | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100146882 |
| 10445052 | 10057528 | 1.6 | 83.5 | null | 2016-02-08 | 2016-02-28 | ECX | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100674598 |
| 10445399 | 10057532 | 1.67 | 75.4 | Curative (C) | 2018-09-24 | 2019-01-06 | Cisplatin +Fluorouracil (3 wk) | 02 | N | UKALL60+ | 100709390 |
| 10445930 | 10057537 | 1.85 | null | Palliative (P) | 2019-08-17 | 2020-09-14 | Abemaciclib | 02 | N | CYTARABINE | 100953445 |
| 10446295 | 10057539 | 0 | 41 | Palliative (P) | 2022-04-25 | 2022-05-12 | AML 18 TRIAL | 02 | N | LENVATINIB | 100157153 |
| 10446379 | 10057541 | 1.5 | 66.4 | null | 2021-10-14 | 2021-10-21 | ABEMACICLIB + FULVESTRANT | 02 | null | CVP R | 100803816 |
| 10446560 | 10057542 | 1.62 | 78.2 | null | 2022-03-08 | 2022-03-08 | null | 02 | null | DASATINIB | 101053470 |
| 10446774 | 10057543 | 1.63 | 71.55 | Adjuvant (A) | 2015-10-31 | 2017-10-05 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | OFATUMUMAB | 100027111 |
| 10446841 | 10057544 | 1.75 | 77 | null | 2020-06-21 | 2020-06-21 | ELOQUENT 2 trial | 02 | null | TRANSPLANT CAR-T CELLS – BREXUCABTAGENE AUTOLEUCEL (KTE-X19) + CYCLOPHOSPHAMIDE + FLUDARABINE | 100546432 |
| 10447006 | 10057545 | 1.62 | 96.15 | Palliative (P) | 2020-11-19 | 2021-05-07 | TRANSPLANT CARMUSTINE + THIOTEPA | 02 | N | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 100738753 |
| 10447146 | 10057548 | 1.64 | 96 | null | 2021-01-16 | 2022-01-30 | Ibrutinib + Rituximab | 02 | null | FIGARO TRIAL | 100066310 |
| 10447365 | 10057550 | 1.58 | 67 | Adjuvant (A) | 2018-01-10 | 2018-01-24 | AML 18 TRIAL | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 100578787 |
| 10447630 | 10057551 | 1.56 | 98.35 | null | 2017-04-25 | 2017-04-25 | GO2 TRIAL | 02 | null | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 101196709 |
| 10447813 | 10057552 | 1.71 | 66.7 | null | 2018-01-13 | 2018-01-26 | MPT | 02 | null | LOMUSTINE | 100270622 |
| 10448026 | 10057554 | 1.7 | 73.1 | Adjuvant (A) | 2022-02-06 | 2022-02-13 | ABEMACICLIB + FULVESTRANT | 02 | N | DASATINIB | 100036696 |
| 10448167 | 10057556 | 1.56 | 92 | 03 | 2019-01-25 | 2019-01-25 | BENDAMUSTINE | null | N | CETUXIMAB + IRINOTECAN + MDG | 100768880 |
| 10448183 | 10057557 | 1.67 | 85.7 | null | 2016-01-31 | 2018-06-07 | FCR | N | null | CYTARABINE | 100469644 |
| 10448389 | 10057560 | 1.68 | 69.4 | Disease modification (D) | 2019-06-24 | 2020-02-15 | null | N | N | IXAZOMIB | 100532477 |
| 10448427 | 10057561 | 1.74 | 71.4 | null | 2018-11-25 | 2018-12-01 | PARTNER Trial | null | null | INTERFERON ALFA | 100597119 |
| 10448603 | 10057562 | 1.67 | 77.3 | null | 2018-02-27 | 2018-02-27 | ETOPOSIDE | 02 | null | ABEMACICLIB + FULVESTRANT | 100765545 |
| 10448673 | 10057563 | null | null | null | 2022-02-13 | 2022-02-26 | ICON8B TRIAL | 02 | null | BCG | 100667505 |
| 10449069 | 10057564 | 1.75 | 55.2 | null | null | 2017-11-15 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 02 | null | AXITINIB | 100751006 |
| 10449361 | 10057567 | 1.68 | 66.3 | Palliative (P) | 2017-07-25 | 2017-08-04 | FLAIR trial | 2 | N | INTERFERON ALFA | 101620296 |
| 10449493 | 10057568 | 1.7 | 84.5 | null | 2017-02-18 | 2018-01-26 | EOX | 02 | null | DASATINIB | 100618672 |